Insulet to Host Investor Day on November 20, 2025

About this update from Insulet Corporation

ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company’s Acton, Massachusetts headquarters on Thursday, November 20, 2025 . The Investor Day will include presentations from the management team highlighting the Company’s longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET) . The Company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at investors.insulet.com under “Events and Presentations.” A replay of the webcast and the related slide presentations will be available on the Company’s website following the event. In-person attendance is by invitation only, and registration is required. About Insulet Corporation : Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts , is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: Insulet.com or omnipod.com . ©2025 Insulet Corporation . Omnipod is a registered trademark of Insulet Corporation . All rights reserved. View source version on businesswire.com : https://www.businesswire.com/news/home/20251010523598/en/ Investor Relations: Clare Trachtman Vice President, Investor Relations (978) 218-0889 [email protected] Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] Source: Insulet Corporation

View stock analysis, news, and events for Insulet Corporation